Kavar Capital Partners Group LLC Has $2.72 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Kavar Capital Partners Group LLC trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 0.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,599 shares of the company’s stock after selling 154 shares during the period. Kavar Capital Partners Group LLC’s holdings in Novo Nordisk A/S were worth $2,718,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth $25,000. Daiwa Securities Group Inc. acquired a new stake in Novo Nordisk A/S during the third quarter worth about $28,000. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S in the 3rd quarter valued at about $42,000. Carolina Wealth Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $48,000. Finally, M&R Capital Management Inc. boosted its position in shares of Novo Nordisk A/S by 260.5% during the 3rd quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock worth $49,000 after acquiring an additional 297 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $87.94 on Monday. The stock has a market cap of $394.65 billion, a price-to-earnings ratio of 28.46, a P/E/G ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The company’s fifty day moving average is $95.35 and its 200 day moving average is $114.80. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on NVO shares. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.